<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/C754D612-4D8B-42CB-922C-07E7F5BE4B49"><gtr:id>C754D612-4D8B-42CB-922C-07E7F5BE4B49</gtr:id><gtr:name>Washington University in St. Louis</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3DBCEE86-6873-4669-9B35-B4EEEAE13F52"><gtr:id>3DBCEE86-6873-4669-9B35-B4EEEAE13F52</gtr:id><gtr:name>Royal Liverpool University NHS Hospitals</gtr:name><gtr:address><gtr:line1>Prescot Street</gtr:line1><gtr:line4>Liverpool</gtr:line4><gtr:postCode>L7 8XP</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/4E777F7E-8B7E-406A-87FB-39A7026F891F"><gtr:id>4E777F7E-8B7E-406A-87FB-39A7026F891F</gtr:id><gtr:name>Uppsala University</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/FC20619C-24CC-4562-8F2A-B1C34FB19874"><gtr:id>FC20619C-24CC-4562-8F2A-B1C34FB19874</gtr:id><gtr:name>University Medical Centre Nijmegen</gtr:name><gtr:address><gtr:line1>Uinversity Medical Centre Nijmegen</gtr:line1><gtr:line2>PO Box 9101</gtr:line2><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/F75103EE-8294-429F-BC9F-70CBED7DA893"><gtr:id>F75103EE-8294-429F-BC9F-70CBED7DA893</gtr:id><gtr:name>St Jude Children's Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/055EA8B7-2C66-4FF5-96DD-63FA3AA7D0B7"><gtr:id>055EA8B7-2C66-4FF5-96DD-63FA3AA7D0B7</gtr:id><gtr:name>London Sch of Hygiene and Trop Medicine</gtr:name><gtr:address><gtr:line1>Keppel Street</gtr:line1><gtr:postCode>WC1E 7HT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/90051600-6EF2-4093-BA8C-2B4B6F550895"><gtr:id>90051600-6EF2-4093-BA8C-2B4B6F550895</gtr:id><gtr:name>University of Dundee</gtr:name><gtr:address><gtr:line1>University of Dundee</gtr:line1><gtr:line2>Nethergate</gtr:line2><gtr:postCode>DD1 4HN</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/A0A585E0-6B0D-4643-A3A6-47943B4CBFEF"><gtr:id>A0A585E0-6B0D-4643-A3A6-47943B4CBFEF</gtr:id><gtr:name>University of Liverpool</gtr:name><gtr:address><gtr:line1>Senate House</gtr:line1><gtr:line2>Abercromby Square</gtr:line2><gtr:line4>Liverpool</gtr:line4><gtr:postCode>L69 3BX</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A0A585E0-6B0D-4643-A3A6-47943B4CBFEF"><gtr:id>A0A585E0-6B0D-4643-A3A6-47943B4CBFEF</gtr:id><gtr:name>University of Liverpool</gtr:name><gtr:address><gtr:line1>Senate House</gtr:line1><gtr:line2>Abercromby Square</gtr:line2><gtr:line4>Liverpool</gtr:line4><gtr:postCode>L69 3BX</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C754D612-4D8B-42CB-922C-07E7F5BE4B49"><gtr:id>C754D612-4D8B-42CB-922C-07E7F5BE4B49</gtr:id><gtr:name>Washington University in St. Louis</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3DBCEE86-6873-4669-9B35-B4EEEAE13F52"><gtr:id>3DBCEE86-6873-4669-9B35-B4EEEAE13F52</gtr:id><gtr:name>Royal Liverpool University NHS Hospitals</gtr:name><gtr:address><gtr:line1>Prescot Street</gtr:line1><gtr:line4>Liverpool</gtr:line4><gtr:postCode>L7 8XP</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4E777F7E-8B7E-406A-87FB-39A7026F891F"><gtr:id>4E777F7E-8B7E-406A-87FB-39A7026F891F</gtr:id><gtr:name>Uppsala University</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/FC20619C-24CC-4562-8F2A-B1C34FB19874"><gtr:id>FC20619C-24CC-4562-8F2A-B1C34FB19874</gtr:id><gtr:name>University Medical Centre Nijmegen</gtr:name><gtr:address><gtr:line1>Uinversity Medical Centre Nijmegen</gtr:line1><gtr:line2>PO Box 9101</gtr:line2><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/F75103EE-8294-429F-BC9F-70CBED7DA893"><gtr:id>F75103EE-8294-429F-BC9F-70CBED7DA893</gtr:id><gtr:name>St Jude Children's Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/055EA8B7-2C66-4FF5-96DD-63FA3AA7D0B7"><gtr:id>055EA8B7-2C66-4FF5-96DD-63FA3AA7D0B7</gtr:id><gtr:name>London Sch of Hygiene and Trop Medicine</gtr:name><gtr:address><gtr:line1>Keppel Street</gtr:line1><gtr:postCode>WC1E 7HT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/90051600-6EF2-4093-BA8C-2B4B6F550895"><gtr:id>90051600-6EF2-4093-BA8C-2B4B6F550895</gtr:id><gtr:name>University of Dundee</gtr:name><gtr:address><gtr:line1>University of Dundee</gtr:line1><gtr:line2>Nethergate</gtr:line2><gtr:postCode>DD1 4HN</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/0EEFD66E-CDB6-4389-910D-FD5045C1C541"><gtr:id>0EEFD66E-CDB6-4389-910D-FD5045C1C541</gtr:id><gtr:firstName>Tjeerd-Pieter</gtr:firstName><gtr:surname>van Staa</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/77F021F2-CB59-421B-9A71-664FE2218FBD"><gtr:id>77F021F2-CB59-421B-9A71-664FE2218FBD</gtr:id><gtr:firstName>Munir</gtr:firstName><gtr:surname>Pirmohamed</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_qA137929"><gtr:id>4EDD8EA4-7746-4F16-932D-741C0CE6E37B</gtr:id><gtr:title>Pharmacogenetics of statin-induced muscle toxicity: exploration using the UK General Practice Research Database (G</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_qA137929</gtr:grantReference><gtr:abstractText>Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.</gtr:abstractText><gtr:technicalSummary>Statins are associated with myotoxicity, but to date, studies investigating genetic predisposition have been small and inconclusive. In the application, we propose the first ever use of GPRD to conduct a pharmacogenetic study. We propose a case-control study design, with patients recruited via GPRD practices. Cases will be patients with a creatine phosphokinase (CPK) level of at least 2x upper limit of normal during statin exposure in presence or absence of muscle symptoms. Saliva sample and patient questionnaires will be collected from cases and controls. The patient questionnaire will include questions on risk factors for myopathy and also questions about the patients willingness to participate in this research. DNA will be analysed using a candidate gene approach, with relevant genes in pathways being assessed (pathway pharmacogentics). The candidate genes will be chosen on the basis of the known pharmacokinetic and pharmacodynamic characteristics of statins. The genes will be analysed for tag SNPs, functional variants and haplotypes, which will then be related to the change in CPK levels. The milestone for this study is to recruit 250 cases and 500 controls and analyse the data within 2 years of the start of the study.</gtr:technicalSummary><gtr:fund><gtr:end>2013-02-22</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2010-04-01</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>326439</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Radboud University Nijmegen Medical Center</gtr:collaboratingOrganisation><gtr:country>Netherlands, Kingdom of the</gtr:country><gtr:description>EU-FP7 award: PREDICTION ADR</gtr:description><gtr:id>E0456650-A752-4185-B41F-287370ABC9A5</gtr:id><gtr:impact>A combined EU FP7 grant of &amp;pound;3million euros was received for a 3 year study.</gtr:impact><gtr:outcomeId>XsaVnD15Pit-3</gtr:outcomeId><gtr:partnerContribution>All partners from Dundee Uppsala and Utrecht universities will contribute patient samples and analysis,</gtr:partnerContribution><gtr:piContribution>We have been succesful in receiving EU-FP7 funding to look at mechanisms of severe adverse drug reactions. This work forms part of the PREDICTION-ADR study Our workpackage will focus on statin myopathy.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>London School of Hygiene and Tropical Medicine (LSHTM)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Statin Web-based Investigation of Side Effects Trial (Statin WISE trial)</gtr:description><gtr:id>20AD281A-F4B2-4361-8141-2AD85990411C</gtr:id><gtr:impact>Multi-disciplinary: pharmacology, genetics, epidemiology, drug safety, medical informatics</gtr:impact><gtr:outcomeId>58bd34fbc76451.58856745-1</gtr:outcomeId><gtr:partnerContribution>The StatinWISE study is funded to and led by LSHTM and UoL is providing the capability to determine key genotypes which predispose study recruits to statin-induced myopathy</gtr:partnerContribution><gtr:piContribution>University of Liverpool is providing genomics capability support for the trial.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Washington</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Cardiovascular Health Research Unit (CHRU)</gtr:department><gtr:description>GWAS meta-analysis</gtr:description><gtr:id>FE90F052-D0C3-42F9-AD2B-9ACA801826B4</gtr:id><gtr:impact>Not yet</gtr:impact><gtr:outcomeId>gzsDQ5hUuCJ-1</gtr:outcomeId><gtr:partnerContribution>GWAS data from their cohort will also be included.</gtr:partnerContribution><gtr:piContribution>We have undertaken a GWAS on our patient samples, and data from this will contribute to a meta-analysis. Analysis will be undertaken jointly as will interpretation.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Dundee</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Biomedical Research Institute</gtr:department><gtr:description>EU-FP7 award: PREDICTION ADR</gtr:description><gtr:id>5326FF58-5E38-4357-92AD-A21EF1B977D3</gtr:id><gtr:impact>A combined EU FP7 grant of &amp;pound;3million euros was received for a 3 year study.</gtr:impact><gtr:outcomeId>XsaVnD15Pit-1</gtr:outcomeId><gtr:partnerContribution>All partners from Dundee Uppsala and Utrecht universities will contribute patient samples and analysis,</gtr:partnerContribution><gtr:piContribution>We have been succesful in receiving EU-FP7 funding to look at mechanisms of severe adverse drug reactions. This work forms part of the PREDICTION-ADR study Our workpackage will focus on statin myopathy.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Royal Liverpool University Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Clinical Chemistry</gtr:description><gtr:id>AF4570D6-2E9D-4E4C-A2EA-13ADBEFD86FE</gtr:id><gtr:impact>Not yet</gtr:impact><gtr:outcomeId>XkVSgYpAp2D-1</gtr:outcomeId><gtr:partnerContribution>Access to database, recruitment of a validation cohort and controls</gtr:partnerContribution><gtr:piContribution>Working jointly for patient identification and recruitment</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>London School of Hygiene and Tropical Medicine (LSHTM)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Statin myopathy genetic validation</gtr:description><gtr:id>C6AD19BB-A5B0-42A7-8CFF-ED80AC265116</gtr:id><gtr:impact>This collaborations is likely to yield a jointly authored publication of the research.</gtr:impact><gtr:outcomeId>5461e1ca45a8e5.47013267-1</gtr:outcomeId><gtr:partnerContribution>They have provided blood/ DNA samples to act as a validation cohort of our GWAS findings.</gtr:partnerContribution><gtr:piContribution>We have genotyped statin myopathy cases provided by Mariam Molokhia as part of a validation analysis of our Genome Wide Association Study</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>St Jude Children's Hospital</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Pharmacogenomics (part of NIH Pharmacogenomics Research Network)</gtr:department><gtr:description>St Judes Hospital</gtr:description><gtr:id>0BA9B041-F50C-4DC4-8821-7EC4EFF9BE68</gtr:id><gtr:impact>Not yet</gtr:impact><gtr:outcomeId>dNMvYHmzCa3-1</gtr:outcomeId><gtr:partnerContribution>Availability of unpublished data on novel and rare variants in SLCO1B1</gtr:partnerContribution><gtr:piContribution>Availability of unpublished data on rare variants in SLCO1B1</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Washington</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Cardiovascular Health Research Unit (CHRU)</gtr:department><gtr:description>Exome sequencing of statin myopathy patients</gtr:description><gtr:id>05D2B9B8-B739-4FCB-806F-1180530FC0AF</gtr:id><gtr:impact>n/a</gtr:impact><gtr:outcomeId>ab53iuB4RNg-1</gtr:outcomeId><gtr:partnerContribution>Scientific consultation, and funding by the US NIH</gtr:partnerContribution><gtr:piContribution>The collaboration involves a large scale exome seuqncing project of cases of statin myopathy - we have contributed samples to this exercise and will be involved in the analysis, interpretation of the data when available, as well as in the submission of manuscripts.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Uppsala University</gtr:collaboratingOrganisation><gtr:country>Sweden, Kingdom of</gtr:country><gtr:description>EU-FP7 award: PREDICTION ADR</gtr:description><gtr:id>875C125B-5CC7-47EE-BB59-5E8F87B0E599</gtr:id><gtr:impact>A combined EU FP7 grant of &amp;pound;3million euros was received for a 3 year study.</gtr:impact><gtr:outcomeId>XsaVnD15Pit-2</gtr:outcomeId><gtr:partnerContribution>All partners from Dundee Uppsala and Utrecht universities will contribute patient samples and analysis,</gtr:partnerContribution><gtr:piContribution>We have been succesful in receiving EU-FP7 funding to look at mechanisms of severe adverse drug reactions. This work forms part of the PREDICTION-ADR study Our workpackage will focus on statin myopathy.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Brighton Science Festival</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>28C549E2-DA2E-49E2-A7F0-280435FA880A</gtr:id><gtr:impact>over 100 people attended the presentation which was entitled: Personalised Medicines. it was held in The Sallis Benney Theatre, 58-67 Grand Parade, Brighton BN2 0JY. It was part of the DNA day at the Brighton Science Festival

A group of medical translators have approached me to do a teaching presentation to their members.</gtr:impact><gtr:outcomeId>jfXbgp55LDr</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Association for Science Education</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>910B62C7-9AFD-42B1-8A00-B06A8E022979</gtr:id><gtr:impact>30 science teachers attended to hear of latest developments in personalised medicine

asked to go and present in shools</gtr:impact><gtr:outcomeId>PZqHaGYqvZH</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Play on Personalised Medicine</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>C442A821-ABFD-4F28-AF8C-9AF9CB7D7034</gtr:id><gtr:impact>This involved a number of activities - (a) an initial workshop with 14-16 year olds and a presentation on personalised medicine to these students, and to a playwright; (b) helping the playwright to develop a play on personalised medicine; (c) commenting on the script; (d) meeting actors who acted in the play and undertaking a general Q&amp;amp;A session; (e) attending the play and taking part in a debate session with members of the general public. All these activities were undertaken with the Y-touring theatre company. Further details available on the website: http://www.theatreofdebate.com/Projects/Dayglo/Story.html

The play was performed in many schools throughout the UK. it also ran for 1 week at the Royal Albert Hall. A DVD of the play which is called &amp;quot;Dayglo&amp;quot; has been made and was shown at the Edinburgh Science Festival, and will also be shown to medical students initially at Liverpool and eventually nationally.</gtr:impact><gtr:outcomeId>gRXG4WeogG8</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2011,2012</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>647547</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>FP7 EU funding award (Prediction ADR)</gtr:description><gtr:end>2016-08-02</gtr:end><gtr:fundingOrg>European Commission</gtr:fundingOrg><gtr:fundingRef>602108</gtr:fundingRef><gtr:id>33DA8EB2-85F9-4EA4-96E7-EF6492DBF4A7</gtr:id><gtr:outcomeId>kevEFLFEK9J</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2013-09-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Report to the Academy of Medical Sciences Review on research governance</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>F3B9E613-24D2-4590-9BF6-9DFC95DC9E01</gtr:id><gtr:outcomeId>U1CfomkHQnA</gtr:outcomeId><gtr:type>Participation in a national consultation</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>We have stored DNA samples from almost 150 patients with statin myopathy, together with 500 controls (statin exposed tolerant patients).</gtr:description><gtr:id>297B7022-44E1-4D9F-ADC7-DF1F52D6EA56</gtr:id><gtr:impact>1. We have written 4 papers from this study illustrating the feasibility of using GPRD for recruitment, validation of case phenotype through genotyping, and epidemiological aspects of statin myopathy.
2. We have just undertaken a GWAS; the data from this will be published and also shared with other researchers to undertake a meta-analysis.
3. Exome sequencing has been undertaken in collaboration with University of Washington, the data from which will be published, and will also be made available for other researchers.</gtr:impact><gtr:outcomeId>RCAtLZAwshM</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Statin myopathy biological archive</gtr:title><gtr:type>Biological samples</gtr:type><gtr:yearFirstProvided>2012</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>43A62F88-8DF7-4A24-81FD-29873340BF27</gtr:id><gtr:title>Electronic health records for biological sample collection: feasibility study of statin-induced myopathy using the Clinical Practice Research Datalink.</gtr:title><gtr:parentPublicationTitle>British journal of clinical pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c5104f0dd1dad91dc21cf8b4e7556932"><gtr:id>c5104f0dd1dad91dc21cf8b4e7556932</gtr:id><gtr:otherNames>O'Meara H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0306-5251</gtr:issn><gtr:outcomeId>pm_540e180e180380be7</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>28A647DB-1B7D-4E8D-AB65-4DAAC2F8D36D</gtr:id><gtr:title>A common missense variant of LILRB5 is associated with statin intolerance and myalgia.</gtr:title><gtr:parentPublicationTitle>European heart journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6cbd2f93107cdf857f5b1d5cff5c4389"><gtr:id>6cbd2f93107cdf857f5b1d5cff5c4389</gtr:id><gtr:otherNames>K Siddiqui M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0195-668X</gtr:issn><gtr:outcomeId>59e09aa6dea191.14875256</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2717ECE6-2AB3-4A33-A836-36C195F6EF46</gtr:id><gtr:title>Pharmacogenetics: past, present and future.</gtr:title><gtr:parentPublicationTitle>Drug discovery today</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e7f5e520a9ef4577b5eb75515fa5bb39"><gtr:id>e7f5e520a9ef4577b5eb75515fa5bb39</gtr:id><gtr:otherNames>Pirmohamed M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1359-6446</gtr:issn><gtr:outcomeId>pm_12583_23_21884816</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F81D0AA5-3A9E-4275-9AB6-573FD071FFD5</gtr:id><gtr:title>Glu83Gly Is Associated With Blunted Creatine Kinase Variation, but Not With Myalgia.</gtr:title><gtr:parentPublicationTitle>Circulation. Cardiovascular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ddac4a30749e7a15a7488cd47d44e8e3"><gtr:id>ddac4a30749e7a15a7488cd47d44e8e3</gtr:id><gtr:otherNames>Siddiqui MK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1942-3268</gtr:issn><gtr:outcomeId>598c1d9e8537a8.08561231</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D79F7CAB-CFC7-4F51-B9B7-B8EF08DC5E68</gtr:id><gtr:title>Phenotype standardization for statin-induced myotoxicity.</gtr:title><gtr:parentPublicationTitle>Clinical pharmacology and therapeutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5866bff6b7be8772b0bc13c9117fba67"><gtr:id>5866bff6b7be8772b0bc13c9117fba67</gtr:id><gtr:otherNames>Alfirevic A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0009-9236</gtr:issn><gtr:outcomeId>545216f6915879.60248565</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4C847120-EFF5-4ACA-9AD2-4F54684E4486</gtr:id><gtr:title>GATM gene variants and statin myopathy risk.</gtr:title><gtr:parentPublicationTitle>Nature</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c9f327f341d1d6e5d479cd9c2652283b"><gtr:id>c9f327f341d1d6e5d479cd9c2652283b</gtr:id><gtr:otherNames>Carr DF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0028-0836</gtr:issn><gtr:outcomeId>54006763402196.90151153</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B2314F08-0EE3-46C3-8DDC-94F2DCE1AFE2</gtr:id><gtr:title>Pharmacogenetics of idiosyncratic adverse drug reactions.</gtr:title><gtr:parentPublicationTitle>Handbook of experimental pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e7f5e520a9ef4577b5eb75515fa5bb39"><gtr:id>e7f5e520a9ef4577b5eb75515fa5bb39</gtr:id><gtr:otherNames>Pirmohamed M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0171-2004</gtr:issn><gtr:outcomeId>pm_12583_23_20020273</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D892CE33-9F25-4640-9373-8305BA234329</gtr:id><gtr:title>Predictors and outcomes of increases in creatine phosphokinase concentrations or rhabdomyolysis risk during statin treatment.</gtr:title><gtr:parentPublicationTitle>British journal of clinical pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9233596b05f45b6d2e3bc13b1650d055"><gtr:id>9233596b05f45b6d2e3bc13b1650d055</gtr:id><gtr:otherNames>van Staa TP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0306-5251</gtr:issn><gtr:outcomeId>54006626b73975.30962819</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FDF87198-8970-4781-B6B4-64F0C6B096F7</gtr:id><gtr:title>Pharmacogenomics in neurology: current state and future steps.</gtr:title><gtr:parentPublicationTitle>Annals of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/87298eb25e04df0efe4e16f397cbf682"><gtr:id>87298eb25e04df0efe4e16f397cbf682</gtr:id><gtr:otherNames>Chan A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0364-5134</gtr:issn><gtr:outcomeId>pm_12583_23_22162054</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>137164DE-3BD8-48EA-8958-00A9658D1311</gtr:id><gtr:title>Pharmacogenomics: Current State-of-the-Art.</gtr:title><gtr:parentPublicationTitle>Genes</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c9f327f341d1d6e5d479cd9c2652283b"><gtr:id>c9f327f341d1d6e5d479cd9c2652283b</gtr:id><gtr:otherNames>Carr DF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2073-4425</gtr:issn><gtr:outcomeId>54006690c681c8.74735866</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>05877B09-88E5-403E-8998-68EB6B4B1C82</gtr:id><gtr:title>SLCO1B1 genetic variant associated with statin-induced myopathy: a proof-of-concept study using the clinical practice research datalink.</gtr:title><gtr:parentPublicationTitle>Clinical pharmacology and therapeutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c9f327f341d1d6e5d479cd9c2652283b"><gtr:id>c9f327f341d1d6e5d479cd9c2652283b</gtr:id><gtr:otherNames>Carr DF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0009-9236</gtr:issn><gtr:outcomeId>pm_12583_23_23942138</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MC_qA137929</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>149FA87E-B8CD-4FFC-B515-EAD312BED03B</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Musculoskeletal</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>9A8BEDCC-D902-4C9A-8CCF-C974265EA3FB</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.4  Surveillance and distribution</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>